40 results about "Non specific" patented technology

The application provides a multifunctional nano particle for targeting abdominal aortic aneurysm and a preparation method and application thereof, and belongs to the field of nanobiomedicine, wherein polyphenol oxidation self-polymer nanoparticles are used as carriers, doxycycline is loaded, and a targeting ligand cRGD is modified on the surface of the nano carrier; the neovasculature in the media and adventitia of AAA sites helps accumulation of the nanoparticles in the abdominal aortic aneurysm, and the integrin αν3 beta receptor highly expressed on the surface of the diseased cell membrane can recognize the cRGD with high affinity, and then mediate the targeted endocytosis of the nanoparticles; after intravenous injection, the nanoparticles can be effectively enriched in the lesion site and achieve long-term retention, and can release DC in response to the high ROS level in the tumor microenvironment; the drug is rapidly released to take effect, and the non-specific toxic side effects are reduced; the free radical scavenging capacity of the nanoparticles can be synergized with the DC activity to treat AAA through multiple mechanisms such as anti-inflammatory, antioxidant, macrophage repolarization promotion, anti-apoptosis and calcification inhibition, and MMPs inhibition.

The present application relates to the technical field of biomedicine, and in particular to a glutamate urea compound, a preparation method and a use thereof, a nuclide targeting probe, a preparation method and a use thereof, and a pharmaceutical composition. The glutamate urea compound and the nuclide targeting probe provided by the present application have excellent in vivo biological properties, high specific uptake in lesions having high PSMA protein expression, high target-to-non-target ratio, low non-specific background activity, and significantly enhanced tumor uptake and retention time, are suitable for use as nuclide treatment and imaging of tumors, can also reduce unnecessary radioactive damage to normal tissues and organs, can overcome the defects of relatively low target organ uptake and excessively short retention time of small molecules acting on PSMA, exhibit improved targeted PSMA nuclide treatment and imaging effects, and have the potential for clinical promotion and application.

According to the DUX4-IGH rearrangement detection primer probe set, the kit and the application, common rearrangement fracture sites of DUX4-IGH are confirmed, an upstream primer is designed on the upstream of a DUX4 transcript, 33 downstream primers are designed according to IGH fracture positions, a universal primer is designed on the upstream of DUX4, and a universal DUX4 probe is designed near the downstream of the primer; interference between the primer probes is small, influence of non-specific amplification is small, the primer probes are suitable for specific detection of multiple DUX4-IGH rearrangement sites, the problem that rearrangement detection is difficult in the prior art is solved, DUX4-IGH fusion transcripts and ABL1 reference genes can be quantitatively detected in a digital PCR instrument through RT-PCR, a basis is provided for auxiliary diagnosis, and the primer probes have remarkable application prospects.

This invention provides a respiratory compensation early warning method and system based on multi-modal behavioral evolution recognition, comprising: continuously acquiring patient behavioral posture data; analyzing the behavioral posture data based on a predefined behavioral evolution knowledge base to identify whether there is a type I posture or a type II posture, wherein the type I posture is a high-frequency non-specific posture that exceeds the individual baseline, and the type II posture is a specific compensatory posture that conforms to a preset specific physiological definition; analyzing the temporal correlation between type I and type II postures, and generating a high-confidence early warning signal if an evolution from type I posture to type II posture is identified. This invention achieves a digital closed loop of clinical cognition: for the first time, it transforms the complete clinical cognition of medical staff—"the patient first becomes restless, then becomes short of breath and sits up"—into a calculable and predictable technical model, which is highly consistent with clinical thinking and easily trusted.

The invention relates to the technical field of molecular biological detection, in particular to a primer probe group and a kit for simultaneously detecting 21 respiratory tract pathogens in a sample and application of the primer probe group and the kit. The primer probe group comprises primer probe sequences as shown in SEQ ID NO. 1 to SEQ ID NO. 75. The primer probe group comprises primer probe sequences as shown in SEQ ID NO. According to the kit, 21 respiratory tract pathogens are detected through seven groups of detection, the total time consumption is about 45 minutes per batch, the detection time is shortened, and the kit has excellent specificity and no non-specific amplification and better meets the requirements of outpatient emergency treatment and fever outpatient service for rapid diagnosis.

This invention relates to the field of biological detection, and more particularly to a monoclonal antibody combination for detecting human IL-8 protein and its application. The combination comprises monoclonal antibodies 2G3 and 3H8. The heavy and light chain variable regions of monoclonal antibody 2G3 include the complementarity-determining regions shown in SEQ ID NO. 1-6; the heavy and light chain variable regions of monoclonal antibody 3H8 include the CDRs shown in SEQ ID NO. 7-12. The antibody combination of this invention exhibits high specificity and effectively avoids cross-reactivity with other CXC chemokine family members, thereby significantly reducing non-specific background interference and the risk of false positives during detection. This invention provides a high-performance, quality-controllable key tool for biological detection for non-diagnostic purposes, research on inflammatory mechanisms, and the development of related scientific reagents.

The invention provides a primer probe combination and a portable kit for African swine fever pathogen detection, and relates to the technical field of biological detection. The primer probe combination comprises an upstream primer, a downstream primer and a probe, the nucleotide sequence of the upstream primer is as shown in SEQ ID NO.7; the nucleotide sequence of the downstream primer is as shown in SEQ ID NO.8; and the nucleotide sequence of the probe is as shown in SEQ ID NO. 9. The primer probe combination adopts a specific sequence obtained by screening SEQ ID NO.7-9, the detection sensitivity reaches 1 copies / T, and non-specific amplification is avoided. Through double labeling of biotin and a fluorophore and modification of tetrahydrofuran and a blocking group, the group is suitable for isothermal amplification and lateral chromatography technologies, visual color development of a specific amplification product can be realized without a variable-temperature instrument, and the group is suitable for low-cost field rapid detection.

The present application relates to the technical field of clinical in vitro detection reagent, especially relates to reagent combination and its application in eliminating MALB reagent non-specific interference detection. When MALB reagent is calibrated at 0 point with purified water, and normal human urine sample is tested on a biochemical instrument, the test value can be 0 or negative, especially when the concentration of urine is 0 mg / L-5 mg / L, the test value is basically 0. The present application selects suitable Malb antibody and suitable antibody feeding amount to improve the sensitivity of reagent, and selects suitable background solution in the reaction system to reduce the non-specific interference of MALB reagent. Not only the problem of 0 or negative sample value is effectively improved, but also the detection accuracy is improved, which has important significance for improving the accuracy of MALB reagent test sample. The reagent combination provided by the present application has good clinical application and large-scale industrial production prospect.

This invention relates to the field of biotechnology, and more particularly to a biomarker, kit, and application for the diagnosis of pancreatic malignant tumors. The biomarker comprises aldehyde-ketone reductase 1B10 protein and carbohydrate antigen 19-9 protein. This biomarker is a secreted serum protein that can specifically distinguish PDAC patients from normal individuals, and from individuals with benign pancreatic diseases, exhibiting high specificity without significant non-specific elevation interference. Combined detection with CA199 can synergistically enhance diagnostic efficacy, significantly reducing the rate of missed diagnoses and misdiagnoses. Simultaneously, this biomarker can assess the postoperative tumor resection effect in PDAC patients, predict whether curative resection is achieved, and provide an effective target for postoperative prognostic monitoring.

The application provides a prognosis risk stratification prediction method for lymph node tumor residue, and belongs to the technical field of risk prediction, and comprises the following steps: acquiring lymph node HE staining sections and immunohistochemical labeling sections, automatically identifying a tumor region of interest by using a U-Net++ network, removing background noise and non-specific staining interference based on a self-adaptive threshold segmentation algorithm, extracting information in four dimensions, and forming a standardized extracted information set; fusing and mapping the extracted information set into a 256-dimensional feature vector set, inputting each vector into a dynamic integrated prediction model, and outputting stratified differential expression of each vector and stratified comprehensive expression of the vector set; determining a risk level based on quantitative threshold values of the stratified differential expression and comparative analysis of risk probabilities of the stratified comprehensive expression, and constructing a multi-dimensional dynamic weight decision model in combination with patient self-state indexes to formulate a personalized scheme. Through multi-modal feature extraction, dynamic integrated modeling and personalized decision-making, precise risk stratification and treatment scheme customization are realized.

The invention discloses a chiral metal organic framework material as well as a preparation method and application thereof, relates to the technical field of medical nano materials, and solves the problems of insufficient targeting specificity and poorer stability of an existing Parkinson's disease treatment drug. The preparation method comprises the following steps: dissolving ZrOCl2. 8H2O, Cu-TCCP and benzoic acid in DMF (Dimethyl Formamide), adding a cysteine aqueous solution, reacting at 30-70 DEG C, heating to 80-120 DEG C, and reacting; and centrifugally collecting a precipitation product, and washing and centrifuging the precipitation product through DMF and ultrapure water to obtain the chiral metal organic framework material. The material has the advantages of good stability, high biocompatibility, simple preparation, low cost, easy amplification and industrial production, overcomes the defects of poor stability, low bioavailability, strong non-specific effect and the like of the traditional alpha-syn inhibitor, and provides a new strategy and an efficient candidate material for early intervention and treatment of Parkinson's disease.

The application provides a method for synchronously detecting multiple cell death modes in a tissue slice based on multiplex immunofluorescence, and belongs to the technical field of biological detection. The application realizes the synchronous labeling and visualization of multiple cell death modes in a single tissue slice, significantly improves the detection efficiency and saves precious samples; by integrating key biomarkers covering main cell death modes in the same detection system, a self-defined interpretation scheme based on multi-marker expression combination is constructed, effectively reducing the error caused by non-specific expression of a single marker, improving the reliability and rationality of the death mode classification, and providing a general solution for rapid screening of complex cell death networks. The application is suitable for anticancer drug efficacy evaluation, combination drug regimen screening and disease mechanism research, and has important scientific research value and clinical conversion prospect.

The application belongs to the technical field of sewage detection, and provides a norovirus GI and GII double genotype synchronous quantitative detection method, which realizes synchronous detection and absolute quantification of norovirus GI and GII in the same reaction tube, does not need to rely on a standard curve, and avoids errors caused by batch differences of standard products; in terms of primer and probe design, the constructed detection system shows high specificity, and even under the coexistence condition of other viruses with close genetic relationship, no non-specific amplification occurs; through gradient dilution experiment verification, the digital PCR method shows good linear response in a wide dynamic range, excellent linear correlation, low repeat variation coefficient, and shows excellent detection consistency and stability; the droplet generation performance is stable, the effective droplet number is always maintained at more than 19500, and the reliability of the quantitative result is ensured.

The invention provides a primer probe combination, a kit, a nucleic acid detection method and application, and relates to the technical field of biochemical detection. The primer probe combination comprises a first primer pair and a first probe, wherein the first primer pair and the first probe are used for specifically amplifying pseudomonas aeruginosa; the second primer pair and the second probe are used for specifically amplifying enterococcus; the third primer pair and the third probe are used for specifically amplifying staphylococcus aureus; the fourth primer pair and the fourth probe are used for specifically amplifying the salmonella enterica. According to the primer and probe combination, a specific nucleotide sequence is utilized, efficient and accurate recognition of pseudomonas aeruginosa, enterococcus, staphylococcus aureus and salmonella enterococcus is achieved in a complex intestinal environment, and non-specific interference is effectively avoided; meanwhile, synchronous quantitative detection of four pathogens is supported, the detection efficiency is remarkably improved, and an accurate and sensitive detection means is provided for rapid clinical evaluation of flora conditions.

The application belongs to the technical field of biological medicine. More specifically, it relates to a preparation and application of in-situ imaging DNA-PROTAC based on strand displacement activation. The novel DNA-PROTAC provided by the application is designed by three modules, which are respectively recruitment module A (E3 ligase ligand-linker-clicking group), locking module B (aptamer-shielded chain double-stranded complex) and activation module C (DNA single strand), three physically separated components, so that the degradation activity is completely silent in the delivery stage. Only after the drug reaches the target area, the in-situ assembly of recruitment module A and locking module B can be triggered by adding activation module C to trigger the strand displacement reaction, thereby effectively avoiding the non-specific activity of traditional degrading agents in the whole body circulation, and significantly reducing the off-target toxicity. In addition, the application converts the large conjugate into multiple independent components with medium and small molecular weights by physical splitting, overcoming the macromolecular delivery barrier.

The utility model provides a sample adding and smearing device for a syphilis non-specific antibody detection test, relates to the technical field of medical instruments, and aims to solve the problems that the device is inconvenient to smear and completely spread samples on different reaction cards at the same time, and when the sample size is large, a long time difference exists between early-stage sample adding and later-stage sample adding, so that the time difference is large. The device comprises a suction tube and a sample adding tube, wherein the suction tube is arranged on the suction tube; a group of fixing blocks are slidably mounted at the outer end of the suction tube, a group of pistons are slidably mounted in the suction tube, and the fixing blocks at the outer end of the suction tube are inserted into limiting grooves in the top of the movable frame; according to the reaction card smearing device, samples on different reaction cards can be conveniently smeared at the same time and completely spread, the use efficiency of the device is effectively improved, the smearing plate can be conveniently and automatically fixed at the horizontal position, and the use effect of the device is further improved.

The invention discloses a reagent, a kit and a detection method for free light chain detection, and relates to the technical field of detection kits, the reagent comprises the following components: a solid phase carrier surface marked with an F (ab ') 2 antibody fragment; the liquid-phase reaction liquid comprises a composite blocking agent for inhibiting non-specific reaction of endogenous interferents; wherein the F (ab ') 2 antibody fragment and the composite blocking agent act together to improve the detection specificity and reaction linearity. The problems that non-specific reaction is caused by an antibody Fc segment and an endogenous interferent when a latex enhanced immunoturbidimetric assay is used for detecting free light chains, existing means cannot eradicate the non-specific reaction, detection linearity is abnormal, and specificity is low are solved, the solid phase carrier marked with the F (ab ') 2 antibody segment and the composite blocking agent are used, and the solid phase carrier marked with the F (ab') 2 antibody segment and the composite blocking agent have a synergistic effect; closed-loop protection is formed from two dimensions of eliminating self interference of the antibody and shielding exogenous interference of the sample, and compared with an antibody optimization or interference shielding means, the combination targeting and detection specificity of a target analyte are synergistically improved.

The application discloses a kind of chronic non-specific lumbar pain treatment data analysis method and device, it is related to medical data analysis processing technical field.Processing method includes: obtaining patient data to be treated;Acupoint graph is handled by segmentation, and local acupoint graph is obtained;According to individual difference data and the individual difference model constructed, the individual difference influence factor data of patient to be treated is obtained, according to individual difference influence factor data and individual difference factor, corresponding individual difference correction factor is obtained;Local acupoint graph is adjusted by optimizing through individual difference correction factor, and acupoint image data is obtained, acupoint analysis coefficient is obtained based on acupoint image data to generate acupoint visual feedback report, and acupoint analysis coefficient is used to quantitatively analyze the acupoint situation of patient to be treated.The technical effect of more accurately analyzing acupoint related treatment data can be achieved by using the application.

The invention provides an application of a serum exosome lncRNA in preparation of a detection product for immune checkpoint inhibitor associated pneumonia, and the serum exosome lncRNA is TTC9-DT, or TTC9-DT and ITGA2-AS1. The invention also provides an application of the serum exosome lncRNA in preparation of a detection product for immune checkpoint inhibitor associated pneumonia. By using the serum exosome lncRNA disclosed by the invention, the sensitivity, the specificity and the accuracy of immune checkpoint inhibitor-related pneumonia diagnosis can be remarkably improved, and compared with a clinical conventional non-specific blood index, the serum exosome lncRNA disclosed by the invention has a better diagnosis effect. In addition, detection can be carried out in a liquid biopsy mode, the method has the advantages of being minimally invasive, capable of achieving real-time monitoring and the like, a detection reagent is low in cost and high in universality, efficient clinical diagnosis and identification can be carried out, the early diagnosis rate is increased, and the method has high clinical application value and wide application prospects.

The application relates to a chiral metal organic framework material and a preparation method and application thereof, relates to the technical field of medical nanomaterials, and solves the problems of insufficient target specificity and poor stability of existing Parkinson's disease treatment drugs. ZrOCl2.8H2O, Cu-TCCP and benzoic acid are dissolved in DMF, a cysteine aqueous solution is added, reaction is carried out at 30-70 DEG C, then the temperature is increased to 80-120 DEG C for reaction; the precipitate is collected by centrifugation, the precipitate is washed by DMF and ultrapure water and centrifuged, and the chiral metal organic framework material is obtained. The material has good stability, high biocompatibility, simple preparation, low cost, easy enlargement and industrialized production, overcomes the defects of poor stability, low bioavailability and strong non-specificity of traditional alpha-syn inhibitors, and provides a new strategy and high-efficiency candidate material for early intervention and treatment of Parkinson's disease.

The invention discloses a dual TaqMan real-time fluorescent quantitative PCR (Polymerase Chain Reaction) detection method for zonal Brucella wild strain infection and an A19 delta bpe275 labeled vaccine strain. The dual TaqMan real-time fluorescent quantitative PCR detection method comprises the following steps: extracting nucleic acid of a sample to be detected; the extracted nucleic acid is taken as a template, fluorescent quantitative PCR amplification is simultaneously carried out in the same reaction system, and the reaction system comprises a first primer probe combination for detecting the bpe275 gene, collecting fluorescent signals of the first fluorescent reporter group and the second fluorescent reporter group, and interpreting the detection result according to the amplification condition of the fluorescent signals. According to the present invention, the non-specific amplification risk is significantly reduced by using the specific primer and probe combination aiming at the bpe275 and bab11216 genes, the accuracy and the reliability of the detection result are ensured, the dual-target detection can be completed in the one-time reaction by using the dual-fluorescence real-time quantitative PCR technology, the detection efficiency is significantly improved, and the kit is suitable for the large-batch sample detection.

The invention discloses an LAMP (loop-mediated isothermal amplification) primer combination for simultaneously detecting influenza A and influenza B viruses and a nucleic acid detection kit, and relates to the technical field of virus detection, the LAMP primer combination for simultaneously detecting the influenza A and influenza B viruses comprises an LAMP primer designed based on an M gene of the influenza A viruses and an LAMP primer designed based on an NS gene of the influenza B viruses; the sequence of the specific primer probe for detecting the influenza A virus is SEQ No.1-7, and the sequence of the specific primer probe for detecting the influenza B virus is SEQ No.8-14. The kit can be used for detecting influenza A and B viruses, is high in detection sensitivity, strong in specificity and simple to operate, and has the following advantages by applying an LAMP probe method: interference of non-specific amplification is more effectively reduced; different fluorophores can be marked by specific probes of different pathogens, so that single-tube multiple detection is realized.

The application discloses a self-assembled aggregation-induced emission nanoprobes for targeted therapy and real-time imaging of non-small cell lung cancer and application, and belongs to the technical field of biological medicine. The self-assembled aggregation-induced emission nanoprobes AIEnps are used for targeting c-Met, and the AIEnps have a dual function: one is to realize real-time imaging through fluorescence tracing, and the other is to realize targeted therapy by inhibiting c-Met. The design based on AIE realizes tumor-specific accumulation and fluorescence tracing, overcomes the limitations of poor tumor permeability and non-specific distribution in traditional therapy, and the AIEnps are a multifunctional NSCLC treatment platform, integrating targeted therapy and real-time imaging, and have a very broad application prospect.

This application relates to methods and kits for detecting the presence or amount of anti-drug antibodies against nanobodies in biological samples. The method includes steps of support adsorption, acid neutralization, specific binding, and electrochemiluminescence detection. The kit also provides a method for detecting the presence or amount of anti-drug antibodies against nanobodies in biological samples. The technical advantage of this application lies in reducing non-specific interference during nanobody detection.

To provide an immunochromatographic device containing a component that can strongly suppress nonspecific reactions without reducing sensitivity, or an immunochromatographic method utilizing said component. [Solution] An immunochromatographic method comprising a membrane having a detection site on which a substance to be detected, which is an antibody or antigen capable of capturing a substance to be detected in a sample, is immobilized, and a label that specifically binds to the substance to be detected, which is an antigen or antibody, is used to form a complex of substance to be detected-substance-substance by antigen-antibody reaction on the detection site on the membrane on which the substance to be detected is immobilized, thereby detecting the substance to be detected by the presence of the label at the detection site by the label, wherein nonspecific reactions are suppressed by including a polyamine in the antigen-antibody reaction system.

The present application relates to a kind of design methods for reducing antibody drug conjugate side effects.The design method includes: analyzing the binding site of antibody and macrophage surface receptor in antibody drug conjugate, carrying out site-directed modification (such as amino acid substitution and chemical modification) on the binding site on antibody, or, screening the competitive blocker of the binding site on receptor, the antibody drug conjugate is combined with the competitive blocker.The present application deeply analyzes the mechanism of adverse reaction induced by ADC drug, first determines the key molecular interface of the accumulation of ADC in macrophage and inflammatory response, and designs corresponding blocking strategy, which can effectively reduce the non-specific uptake of ADC in macrophage and inflammatory response, while not affecting its therapeutic activity, so as to realize the safety optimization of ADC drug.

The invention is applicable to the technical field of biological medicine, and provides a brain-targeting and electrical stimulation responsive nano system and a preparation method and application thereof, and the preparation method comprises the following steps: preparing PPY / PDA-CeO2 composite nanoparticles; carrying out surface PEGylation modification; and coupling of a brain targeting ligand ANG. Aiming at the defects of low delivery efficiency and lack of space-time controllability of the existing therapeutic drug, the invention constructs a brain targeting and electrical stimulation responsive nano system, which can penetrate through BBB in a targeting manner and enrich in epilepsy focus, significantly improves the bioavailability of the drug in the brain, reduces the non-specific distribution of the drug in peripheral organs, and reduces the toxic and side effects of the whole body; meanwhile, the nano material can be released in an electric response mode, controllable treatment on epilepsy lesions is achieved, oxidative stress and neuroinflammation at the lesions are effectively relieved, the nerve protection effect is achieved, and good clinical transformation prospects are achieved.

The application belongs to the technical field of biological medicine, and particularly relates to glutamic acid urea compounds and a preparation method and application thereof, a nuclide targeting probe and a preparation method and application thereof, and a pharmaceutical composition. The glutamic acid urea compounds and the nuclide targeting probe provided by the application have excellent in-vivo biological performance, have high specific uptake in a lesion with high expression of PSMA protein, have a high target-to-non-target ratio, have low non-specific background activity, have significantly enhanced tumor uptake and retention time, are suitable for being used as nuclide treatment and imaging of tumors, can reduce unnecessary radioactive damage to normal tissues and organs, can overcome the defects of low uptake of small-molecule PSMA target organs and short retention time, can improve the effect of targeted PSMA nuclide treatment and imaging, and have potential for clinical popularization and application.

The invention provides a composition and a kit for detecting combined methylation of CpG sites in an MLH1 gene target region in human tumor tissues and application of the composition and the kit. The CpG locus combination in the MLH1 gene target area in the human tumor tissue provided by the invention comprises 10 CpG loci which have the most significant difference with methylation states in sporadic and Lingchi syndrome related tumors in the MLH1 gene. The detection composition is designed on the basis of 10 CpG loci, competitive Blocker oligonucleotides are introduced into the detection composition and can be specifically combined with a conversion sequence corresponding to non-methylated DNA, non-specific amplification of the detection composition is effectively inhibited in the early stage of PCR amplification, the common problem of'tail raising 'or background rising in conventional qPCR is thoroughly solved, and the detection composition has the advantages of high specificity, high sensitivity and the like. It is ensured that amplification signals are completely derived from target methylation alleles, the detection specificity is close to 100%, and extremely high confidence is provided for clinical diagnosis.

This invention belongs to the field of biodetection technology and relates to a method for specifically detecting wild-type virus residues in modified viral products and its application. This invention significantly suppresses non-specific extension into a mutant background by using LNA-modified primers; simultaneously, the SNP-embedded probe design differentiates at the signal level, amplifying the fluorescence signal differences between wild-type and mutant sequences. Finally, the ddPCR platform effectively eliminates PCR inhibitors and background noise from non-specific amplification. These three factors synergistically produce a significant enhancement effect. Taking VSV as an example, the embodiments demonstrate that this method can stably and repeatedly detect wild-type virus with a proportion as low as 1 / (10^7) against a mutant virus background of up to 10^10 copies, achieving a sensitivity at the part-in-ten-millions level. This represents an improvement of at least four orders of magnitude compared to traditional methods, far exceeding the reasonable expectations of those skilled in the art based on conventional technological improvements.